Trinity Biotech plc (NASDAQ:TRIB) Sees Significant Drop in Short Interest

Trinity Biotech plc (NASDAQ:TRIB) was the recipient of a large decrease in short interest in the month of September. As of September 15th, there was short interest totalling 89,700 shares, a decrease of 57.9% from the August 31st total of 213,200 shares. Currently, 0.8% of the company’s stock are sold short. Based on an average daily volume of 1,280,000 shares, the short-interest ratio is presently 0.1 days.

Analyst Upgrades and Downgrades

Separately, StockNews.com initiated coverage on shares of Trinity Biotech in a report on Friday, August 30th. They set a “buy” rating on the stock.

Trinity Biotech Trading Down 4.8 %

Shares of NASDAQ:TRIB opened at $1.19 on Thursday. The company has a market capitalization of $9.07 million, a PE ratio of -0.43 and a beta of 1.22. Trinity Biotech has a 12-month low of $1.15 and a 12-month high of $3.75. The business’s fifty day simple moving average is $2.24 and its 200-day simple moving average is $2.12.

Trinity Biotech (NASDAQ:TRIB) last announced its earnings results on Wednesday, August 14th. The company reported ($0.55) EPS for the quarter, topping analysts’ consensus estimates of ($0.65) by $0.10. The firm had revenue of $15.84 million during the quarter, compared to the consensus estimate of $15.75 million. Research analysts predict that Trinity Biotech will post -1.91 EPS for the current year.

Trinity Biotech Company Profile

Trinity Biotech plc acquires, together with its subsidiaries, develops, acquires, manufactures, and markets medical diagnostic products for the clinical laboratory and point-of-care (POC) segments of the diagnostic market in the Americas and Ireland. The company offers clinical laboratory products, including diagnostic tests and instrumentation, which detects infectious diseases; sexually transmitted diseases consisting of syphilis and herpes; SARS-CoV-2; and epstein barr, measles, mumps, toxoplasmosis, cytomegalovirus, rubella, varicella and other viral pathogens, as well as products for the in-vitro diagnostic testing for haemoglobin A1c used in the monitoring and diagnosis of diabetes, and identifying those who are at a risk of developing diabetes.